Quest Diagnostics Inc (DGX)

DGX (NYSE:Health Services) EQUITY
pos +0.00
Today's Range: 107.77 - 108.61 | DGX Avg Daily Volume: 878,800
Last Update: 05/26/17 - 4:02 PM EDT
Volume: 0
YTD Performance: 17.50%
Open: $0.00
Previous Close: $108.14
52 Week Range: $75.20 - $108.61
Oustanding Shares: 136,825,521
Market Cap: 14,796,311,841
6-Month Chart
TheStreet Ratings Grade for DGX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 3 3
Moderate Buy 1 1 0 0
Hold 13 12 13 12
Moderate Sell 0 0 0 1
Strong Sell 1 1 1 1
Mean Rec. 2.68 2.66 2.72 2.78
Latest Dividend: 0.45
Latest Dividend Yield: 1.66%
Dividend Ex-Date: 07/06/17
Price Earnings Ratio: 21.80
Price Earnings Comparisons:
DGX Sector Avg. S&P 500
21.80 21.80 29.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.96% 39.80% 87.99%
Revenue 0.30 0.10 0.02
Net Income -4.70 -0.20 -0.06
EPS -7.40 -0.20 -0.06
Earnings for DGX:
Revenue 7.52B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.41 $1.43 $5.56 $5.84
Number of Analysts 13 12 14 14
High Estimate $1.43 $1.46 $5.60 $6.00
Low Estimate $1.38 $1.37 $5.50 $5.72
Prior Year $1.34 $1.37 $5.15 $5.56
Growth Rate (Year over Year) 5.45% 4.26% 7.89% 5.18%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
It's a wonder to me how split this market really is.
Apr 21, 2017 | 8:58 AM EDT
Raymond James upgraded Quest Diagnostics to "Outperform" from "Market Perform" to  with a price target of $116.
Dec 12, 2016 | 7:37 AM EST
DGX was upgraded to Buy, Goldman Sachs said. $102 price target. Company can gain market share and realize operating leverage.
Here's a window into what institutional investors may be doing and how to profit from that.
Let me give you the unassailable themes.
LH's $5.7B Covance takeover could be just what the doctor ordered.
Charts show DGX should break out above resistance soon.
Questions will continue to swirl until facts emerge.
Oct 16, 2015 | 7:07 AM EDT
DGX was upgraded from Underperform to Market Perform, Wells Fargo said. Valuation call.  
Quest could be vulnerable to a deep correction, but a decline to next support around $60 seems like the path of least resistance. 

Columnist Conversations

DIS has been green since the opening bell and is trading at its best levels of the week with less than 30 minu...
Looks like RUTH will finish the week at new 2017 highs.  Still has room to run, not overbought(MACD).&nbs...
A big THANK YOU to all the men and women in uniform this weekend, and for those who served and paid the ultima...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.